Prostate Cancer Clinical Trial

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer

Summary

This study is being proposed to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients. Quality of life outcomes as well as gastrointestinal and genitourinary early and late toxicities will be analyzed and compared to conventional proton therapy regimens. It is thought that this regimen will produce comparable findings and would result in substantial health care cost savings, as well as, be more convenient for patients.

View Full Description

Full Description

Patients will receive: 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathological (histologically) proven diagnosis of prostatic adenocarcinoma within 365 days (1 year) prior to study registration.

History and physical exam with digital rectal exam of the prostate to establish clinical staging
Clinical stage T1-T2c (AJCC 7th edition) within 90 days of registration.
Prostate specific antigen (PSA) < 20 ng/mL within 90 days prior to registration.
Gleason Score < 7.
Eastern Cooperative Oncology Group(ECOG) Performance status 0-1.
Clinically negative lymph nodes evaluated by imaging (pelvic +/- abdominal CT or MRI scan).
Patients with lymph nodes equivocal or questionable by imaging are eligible without biopsy if the nodes are ≤ 1.5 cm in diameter; any node larger than this on imaging will require negative biopsy for eligibility, unless the node is know to be enlarged from prior scans and considered stable, per discretion of the treating physician.
Patients must be 18 years of age or older.
Patient must be able to provide study-specific informed consent prior to study entry.
Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire.
No evidence of bone metastases (M0) on bone scan within 60 days prior to registration.
Bone scan is not required for patients enrolled with a single intermediate risk factor only, but this scan may be obtained at the discretion of the treating physician. Patients with 2 or 3 risk factors will require a negative bone scan for eligibility.
Equivocal bone scan findings are allowed if plain film x-rays are negative for metastasis.
Patient is able to start proton therapy or neo-adjuvant hormonal therapy, when recommended, within 12 weeks of registration.
No prior radiotherapy to the pelvic area.
No prior prostate cancer therapy such as: prostatectomy, cryotherapy, chemotherapy or hyperthermia.
Platelets ≥ 100,000 cells/mm3, Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3, Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
Obs.: Patients with high risk factors, such as T3, Gleason 8-10 or PSA > 20ng/mL who are not considered candidates for pelvic lymph node radiation treatment are still considered eligible for this study.

Exclusion Criteria:

• Prior radiotherapy to the pelvic area.

Prior prostate cancer therapy such as: prostatectomy, cryotherapy, or hyperthermia.
Prior systemic therapy (chemotherapy) for prostate cancer.
Evidence of distant metastases.
Regional lymph node involvement.
Previous or concurrent cytotoxic chemotherapy for prostate cancer.
Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition. Note however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immune-compromised patients.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

235

Study ID:

NCT02040610

Recruitment Status:

Recruiting

Sponsor:

Provision Center for Proton Therapy

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Provision Cares Proton Therapy Center Knoxville
Knoxville Tennessee, 37909, United States More Info
Natalie E Freeman, PhD
Contact
8659342672
[email protected]
Brenda Whitehead, CCRP
Contact
8652433278
[email protected]
J. Ben Wilkinson, M.D.
Principal Investigator
Allen Meek, M.D.
Sub-Investigator
Provision Cares Proton Therapy Center Nashville
Nashville Tennessee, 37067, United States More Info
Natalie E Freeman, PhD
Contact
865-934-2672
[email protected]
Wil J Rivers, BS
Contact
6157164736
[email protected]
James Gray, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

235

Study ID:

NCT02040610

Recruitment Status:

Recruiting

Sponsor:


Provision Center for Proton Therapy

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider